ArticleJournal of thrombosis and thrombolysis2026
Machine learning to identify novel bleeding and residual thromboembolic risks in patients on anticoagulation.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Balancing thromboembolic prevention against bleeding risk remains a key challenge during oral anticoagulant (OAC) therapy. CHA₂DS₂-VASc cannot predict residual thromboembolic risk, and HAS-BLED has insufficient predictive ability for direct oral anticoagulants (DOACs).While machine learning offers a transformative paradigm for risk assessment, its clinical application is often hindered by three critical challenges: data imbalance caused by low incidence of embolism and hemorrhage, the omission of drug metabolism-related features, and limited generalizability across diverse DOAC regimens. We retrospectively collected clinical data from patients receiving OAC in the First Affiliated Hospital of Soochow University from 2018 to 2024. To address data imbalance, we recruited patients in case-control manner, then implemented a non-boundary oversampling strategy. To investigate more valuable predictors, we incorporated drug metabolism-related features as potential predictors to develop robust models. Shapley Additive exPlanations (SHAP) analysis supports the global and local interpretation for prediction, validating the contribution of predictors and enhancing the credibility of models in clinic. 281 patients with bleeding events, 213 patients with thromboembolic events, and 978 as negatvie control were recruited. The overall dataset for bleeding risk prediction included 1,259 patients (positive-to-negative ratio ≈ 1:3.48), and that for thromboembolism risk prediction included 1,191 patients (positive-to-negative ratio ≈ 1:4.59). The Light Gradient Boosting Machine (LGBM) achieved an AUC of 0.880 for predicting bleeding risk, outperformed the HAS-BLED score (AUC = 0.730). The Logistic Regression (LR) for predicting thromboembolic risk achieved an AUC of 0.792, outperformed the CHA₂DS₂-VASc score (AUC = 0.628). Decision curve analysis further suggested that these models provided meaningful clinical net benefit within reasonable threshold ranges. SHAP identified pulmonary artery pressure (PAP), left atrial volume index (LAVI), platelet count, and left atrial appendage (LAA) volume as key predictors of thromboembolic risk, while estimated glomerular filtration rate (eGFR), body mass index (BMI), and direct bilirubin were key predictors of bleeding risk, consistent with clinical expectations. By integrating diverse clinical indicators, prioritizing collection of positive events, and applying a new data augmentation, we identified several novel predictors, including PAP, LAVI, platelet count, LAA volume, eGFR, and BMI. Compared with traditional risk scores, the new models suggested superior predictive performance, providing robust evidence-based support for personalized clinical decision-making.
Indexed as
Identifiers
42301346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.